Brazil and Argentina Join Talks To Create Latin American & Caribbean Regulator

The number of regulators formally agreeing to work towards creating a Latin American regulator is growing.

Bridge
Latin American Regulators Aim To Build Trust To Bridge Regulatory Gaps • Source: Shutterstock

Two of Latin America’s most well-established regulators, Brazil’s Anvisa and Argentina’s Anmat, have signed up to moving ahead to create a medicines regulator for Latin America and the Caribbean. The addition of the two influential bodies could help drive the project forward, after it was initiated by three other regulatory agencies earlier this year.

Cofepris, Invima and Cecmed, regulators in Mexico, Colombia and Cuba respectively, signed the Acapulco Declaration In April to formalize talks...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Latin America

New Drug Procurement Rules Aim To Drive Pharma Investment In Mexico

 

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

Brazil Could Look To Germany, UK And Australia For ATMP Drug Pricing Rules

 

There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.

Argentina Speeds Up Market Access Process

 

Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.

Brazil’s Drug Pricing Shake Up Calls For More Robust Evidence From Companies

 

Brazil’s drug pricing authorities are planning to introduce, among other things, a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.

More from Geography

Animal Testing Alternatives: US Pharmacopeia On Its Testing Transition

 

In this second of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet which animal testing models have alternative options and highlights where further investment and research is needed to develop appropriate alternatives.

EU Industry Proposes 3-Basket Strategy To Phase Out Animal Testing

 

A “basket approach” to phasing out animal testing could help identify areas where “moonshot” research is required to implement new approach methodologies, according to EU industry federation EFPIA.

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.